BiotechTube

Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implant

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bleeding

Conditions

Bleeding

Trial Timeline

Sep 1, 2011 → —

NCT ID
NCT01438736

About Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implant

Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) + Etonogestrel 68 mg subdermal implant is a approved stage product being developed by Merck for Bleeding. The current trial status is unknown. This product is registered under clinical trial identifier NCT01438736. Target conditions include Bleeding.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01438736ApprovedUNKNOWN

Competing Products

20 competing products in Bleeding

See all competitors
ProductCompanyStageHype Score
60mg edoxaban + 180mg edoxaban + 50 IU/kg Beriplex P/N + 25 IU/kg Beriplex P/N + 10 IU/kg Beriplex P/NDaiichi SankyoPhase 1
33
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
52
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
52
Elagolix + Estradiol /norethindrone acetate (E2/NETA)AbbViePhase 3
77
Risk of selected safety eventsAstraZenecaPre-clinical
23
AnticoagulantAstraZenecaPre-clinical
23
Esomeprazole Na + Cimetidine + Esomeprazole MgAstraZenecaPhase 3
77
Tamoxifen + Placebo + Tamoxifen (open label)MerckApproved
85
Placebo + CurcuminMerckApproved
85
Octreotide LAR DepotNovartisPhase 1
33
activated recombinant human factor VIINovo NordiskPre-clinical
22
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
76
catridecacog + recombinant factor XIIINovo NordiskPhase 1
32
eptacog alfa (activated) + placeboNovo NordiskPhase 3
76
activated recombinant human factor VII + activated recombinant human factor VIINovo NordiskPhase 1
32
activated recombinant human factor VIINovo NordiskPhase 2
51
autologous stored plateletsNovo NordiskPhase 2
51
turoctocog alfa pegolNovo NordiskPhase 3
76
recombinant factor XIIINovo NordiskPre-clinical
22
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
32

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85